The CEACAM1-derived peptide QLSN impairs collagen-induced human platelet activation through glycoprotein VI

Area of Science:

• Biochemistry
• Hematology
• Molecular Biology

Background:

• Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) regulates platelet activation via its intracellular motifs.
• The functional role of CEACAM1's extracellular fragments remains largely unexplored.

Purpose of the Study:

• To investigate the function of CEACAM1's extracellular cleavage fragments.
• To identify potential antiplatelet agents derived from CEACAM1.

Main Methods:

• Mass spectrometry (MS) was employed to identify CEACAM1 cleavage fragments generated by matrix metallopeptidase 12 (MMP-12).
• Synthesized peptides corresponding to identified fragments were tested for their effects on platelet aggregation, adhesion, and activation.
• Western blotting was used to assess signaling pathway activation (Src, Akt, Syk, PLCγ2) in response to peptide treatment.

Main Results:

• MS identified 9 MMP-12-shed CEACAM1 fragments; the peptide QLSN from the A1-domain significantly attenuated collagen-induced platelet aggregation and adhesion.
• QLSN reduced human platelet secretion and integrin α_IIbβ₃ activation triggered by the glycoprotein VI (GPVI)-selective agonist, convulxin.
• QLSN treatment decreased convulxin-mediated phosphorylation of key signaling molecules, including Src, Akt, Syk, and PLCγ2, in human platelets.

Conclusions:

• The CEACAM1-derived peptide QLSN demonstrates potent inhibition of GPVI-mediated human platelet activation.
• QLSN represents a promising candidate for the development of novel antiplatelet therapies.